Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2006 Mar;47(3):257-262. Korean.
    Published online Mar 31, 2006.
    https://doi.org/10.4111/kju.2006.47.3.257
    Copyright © 2006 The Korean Urological Association
    Original Article

    Voiding Dysfunction of Men is Associated with Metabolic Syndrome

    Jae Hun Kim, Bong Suk Shim, Jae Sik Kim and Young Sun Hong1
      • Department of Urology, College of Medicine, Ewha Womans University, Seoul, Korea.
      • 1Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea.
    • Corresponding author (Email: bonstone@ewha.ac.kr )
    Received July 05, 2005; Accepted September 12, 2005.

    Abstract

    Purpose

    With the recent changes in eating habits and the westernization of peoples' lifestyle, the occurrence of coronary artery disease is on the rise. In 1998, the World Health Organization (WHO) defined "metabolic syndrome" as a condition in which all the risk factors of coronary artery disease exist in an elderly individual. We investigated the relationship between metabolic syndrome and voiding difficulty.

    Materials and Methods

    In 2004, we investigated 123 male out-patients who visited the endocrinology department and the health care center between the months of March and October. We divided the patients into two groups: one group met the criteria for metabolic syndrome (n=90, 58.7±8.9 years old) and one group didn't met the criteria (n=33, 57.8±9.5 years old), and we compared factors of voiding difficulty between the these two groups.

    Results

    When comparing the components of metabolic syndrome in the patient study group to the control study group, the metabolic syndrome patients scored poorly for all the metabolic syndrome components in comparison to the control group (p<0.05). When comparing the voiding factors of the metabolic syndrome patients to the control group, the metabolic syndrome patient group scored substantially lower than the control group for all the voiding factors (p<0.05).

    Conclusions

    The results of this study proved that metabolic syndrome and voiding difficulty are related. Therefore, the earlier diagnosis of metabolic syndrome should be possible by performing a more active investigation for metabolic syndrome in the patients who are admitted with voiding difficulty.

    Keywords
    Benign prostatic hyperplasia; Metabolic syndrome X; Urination disorder

    Tables

    Table 1
    Comparison of factors of metabolic syndrome between the metabolic syndrome group and the control group

    Table 2
    Voiding factors of the metabolic syndrome group and the control group

    Table 3
    Comparison of voiding dysfunction between the MS group and the control group, according to ICS standardization

    Table 4
    Voiding factors of the type II DM group and the non-type II DM group in the metabolic syndrome group

    Table 5
    Voiding factors of the type II DM≥5 years group and the type II DM<5 years group

    References

      1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silvershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847.
      1. Fuster V, Pearson TA. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:957–1047.
      1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.
      1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173–194.
      1. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J 1994;15 Suppl C:78–81.
      1. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001;2:297–301.
      1. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390–1393.
      1. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157–162.
      1. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151–158.
      1. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori 2004;52:291–294.
      1. Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003;22 Suppl 2:35–43.
      1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–178.
      1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Excutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
      1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.
      1. Western Pacific Regional Office of the World Health Organization, The International Obesity Task Force. Sydney: Health Communications Australia; 2000. The Asia-Pacific perspective: redefining obesity and its treatment.
        http://www.obesityasiapacific.com.
      1. Nugent AP. The metabolic syndrome. BNF Nutr Bull 2004;29:36–43.
      1. Lym YL, Hwang SW, Shim HJ, Oh EH, Chang YS, Cho BL. Prevalence and risk factors of the metabolic syndrome as defined by NCEP-ATP III. J Korean Acad Fam Med 2003;24:135–143.
      1. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081–1090.
      1. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia 1989;32 Suppl:465A.
      1. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725–1729.
      1. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914–1923.
      1. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599–604.
      1. Giugliano F, Esposito K, Di Palo C, Ciotola M, Giugliano G, Marfella R, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 2004;27:665–669.
      1. Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol 2003;10:569–574.
      1. Saito M, Ohmura M, Kondo A. Effect of ageing on blood flow to the bladder and bladder function. Urol Int 1999;62:93–98.
      1. Lau DH, Kommu S, Mikhailidis DP, Morgan RJ, Mumtaz FH. Re: the prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2005;173:1050.
      1. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17:477–486.
      1. Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM. Glucose, insulin, and lipid metabolism in doxazosintreated patients with hypertension. Am J Hypertens 1992;5:827–831.
      1. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415–420.
      1. Swislocki AL, Hoffman BB, Sheu WH, Chen YD, Reaven GM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989;86:14–18.
    Cited by
    Crossref 10
    Google Scholar 
    Scopus 9
    MeSH Terms
    Aged
    Coronary Artery Disease
    Delivery of Health Care
    Diagnosis
    Eating
    Endocrinology
    Humans
    Life Style
    Male
    Metabolic Syndrome X
    Multiple Endocrine Neoplasia Type 1*
    Outpatients
    Prostatic Hyperplasia
    Risk Factors
    Urination Disorders
    World Health Organization
    Metrics
    Share
    Tables
    slide
    slide
    slide
    slide
    slide

    1 / 5

    PERMALINK